Presentation
Related topics:
Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, IT & Big Data, Global (non-specific), Digital & Technology, Life Sciences (not-specific)
Availability: FREE
- Necessary conditions for better, more useful real-world data.
- Importance of a comprehensive and robust RWE strategy, including identification of optimal data sources, methods, and data gaps.
- The use of technology in data analytics for increased cost savings and decreased time for results
Speaker
Radek Wasiak
Vice President, Meta Research & Real-World Evidence,
Evidera Inc., UK
Presentation
Related topics:
Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Global (non-specific), Regulations & Ethics, Life Sciences (not-specific)
Availability: FREE
- Regulatory classification of real-world studies.
- Why are the regulations for non-interventional studies so difficult/frustrating/confusing?
- Pragmatic clinical trials: The missing RWE link?
Speaker
Stuart McCully
VP Late Stage
INC Research/inVentiv Health, UK
Presentation
Related topics:
Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Global (non-specific), Life Sciences (not-specific)
Availability: FREE
- Post-marketing commitments: PASS, PAES.
- Article 20s and DUS: Prospective or retrospective data.
- ENCePP: How to make the most of it.
- Leveraging innovation to meet commitments.
- Real World Evidence 3.0.
Speaker
Alexandre Malouvier
Director of Scientific Affairs, Late Phase Services
PRA Health Sciences, UK
Presentation
Related topics:
Medical Affairs & Stakeholder Engagement, Global (non-specific), Life Sciences (not-specific)
Availability: FREE
- Why medical affairs must adapt and consider this educational format to engage physicians.
- What is the value of IME?: Benefits and considerations in funding IME/CME.
- Interactive case study of IME, identifying best practices to providing IME/CME.
Speaker
Celeste Kolanko
Managing Director
Liberum IME, UK
Presentation
Related topics:
Market Access & HEOR, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Global (non-specific), Life Sciences (not-specific)
Availability: FREE
- Regulator and payer perspectives on patient-centric data in decision making.
- Highly successful strategies for leveraging the patient voice in RWE research.
Speakers
Leanne Larson
Corporate VP, Observational Research
PAREXEL
Oliver Leatham
VP Heron Commercialization
PAREXEL
Presentation
Related topics:
Medical Affairs & Stakeholder Engagement, Global (non-specific), Patient-Centricity & Care, Life Sciences (not-specific)
Availability: FREE
- Identify key questions that should be asked when determining if medical communications are meaningful for patients.
- Working with stakeholders to provide insights for patient-centric communications.
- Describe two case studies that demonstrate how medical communications to patients were vastly improved by applying patient insights.
Speaker
William C Maier
Chief Scientific Officer and Head of Patient-Centered Sciences
Mapi Group
Presentation
Related topics:
Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Life Sciences (not-specific)
Availability: FREE
- Transformation of medical affairs to deliver greater value.
- Executing long term engagement strategies in today’s complex disease space.
- Developing and delivering scientific insights to achieve strategic differentiation.
Speaker
Sital Kotecha
Director, Medical Strategy
Veeva Systems, UK
Presentation
Related topics:
Pharmaceutical/Biotech, Market Access & HEOR, Global (non-specific), Capabilities & Effectiveness
Availability: FREE
- New organisational capability needs to address major market changes.
- Optimising global strategy and local agility: Updated planning and governance structures.
- Cross-functional leadership and aligned KPIs.
- Digital tools to drive efficiency, effectiveness and feedback.
Speaker
Chris Easley
Head of Market Access Solutions
Pope Woodhead and Associates Ltd.
Presentation
Related topics:
Pharmaceutical/Biotech, Market Access & HEOR, Global (non-specific)
Availability: FREE
- How a product’s characteristics or attributes contribute to both individual willingness to pay and “value” from different perspectives (e.g., stakeholder, society).
- The various methodologies through which attribute value can be assessed.
- A real-world case study of how decision-analytic modelling helped a leading medical device company establish the value of a unique product attribute, and by so doing justify higher tender pricing in a key EU market.
Speaker
Mason W. Russell
Vice President, Strategic Consulting (Life Sciences)
Truven, USA
Presentation
Related topics:
Pharmaceutical/Biotech, Market Access & HEOR, Global (non-specific), Capabilities & Effectiveness
Availability: FREE
- Organisational excellence provides the bridge from strategy to results.
- What are the building blocks of the bridge and what gets missed.
- How should we apply organisational excellence to market access strategy.
- What can we learn from other industries?
Speaker
Janice Haigh
Vice President, Pricing & Market Access
PAREXEL
Presentation
Related topics:
Pharmaceutical/Biotech, Market Access & HEOR, Global (non-specific)
Availability: FREE
- Understanding payer attitudes to optimise business performance.
- What is the optimal reach and frequency of a payer tracker to maximise impact of such an approach.
- How can payer trackers can be utilised to leverage business performance.
- Benefit of payer trackers when sharing information with key internal stakeholders.
Speaker
Santanu Das
Vice President
GFK, UK
Presentation
Related topics:
Pharmaceutical/Biotech, Market Access & HEOR, Global (non-specific)
Availability: FREE
Most developed countries apply some form of IRP as a factor in negotiating or regulating domestic pricing. With the emergence of risk sharing agreements and in particular confidential price / volume agreements tied to HTA assessments some experts are suggesting the end of IRP systems in imminent. In contrast, some countries like Canada are placing greater reliance on IRP to lower drug prices.
- Beginnings and Evolution of IRP.
- Overview of approaches to IRP.
- Impact of IRP on product launches and HTA.
- Role of risk-sharing agreements to mitigate impact of IRP.
- Canadian IRP as a case study.
Speaker
Neil Palmer
Founder & Senior Consultant
PDCI Market Access
Presentation
Related topics:
Pharmaceutical/Biotech, Market Access & HEOR, Medical Affairs & Stakeholder Engagement, Patient-Centricity & Care, Digital & Technology
Availability: FREE
- The revolution has already happened in other sectors: Is health next?
- How is digital technology being deployed along the health value chain?
- How will technology change patient, physician and payer engagement?
- Can technology radically change data collection and analysis in clinical trials and the real world and therefore the assessment of value?
Speaker
Giles Thurston
Head of Digital Solutions
Pope Woodhead and Associates Ltd.
Presentation
Related topics:
Pharmaceutical/Biotech, Europe, Market Access & HEOR
Availability: FREE
- Current perception of PRO evidence among payers and its influence in decision-making
- Differences between payer and regulators in assessing PRO evidence
Speaker
Anke van Engen
Principal, Consulting Services
QuintilesIMS
Presentation
Related topics:
Pharmaceutical/Biotech, Europe, Market Access & HEOR
Availability: FREE
- How similar are HTA agencies in methods and procedures?
- Is there a development towards shared standards?
- What are stakeholders doing to encourage harmonisation/standardisation?
- Is there a need for a European institution to get the job done?
Speaker
Finn Boerlum Kristensen
Managing Director Science & Policy, Faculty of Health Sciences, University of Southern Denmark
Former EUnetHTA Executive, Committee Chairman and EUnetHTA Secretariat Director
Presentation
Related topics:
Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Commercial, Global (non-specific), Medical Science Liaison, Life Sciences (not-specific)
Availability: FREE
- Medical Affairs and MSL synchronicity: Linking efforts to ensure a positive outcome.
- MSLs and KOLs: The data sweet spot: Finding balance within the current regulatory environment.
- The role of MSLs in audience engagement: Strategic & tactical approaches to engagement.
- MSL-directed educational communications: An appropriate path forward.
- Measuring the impact of MSL-driven activities: Applying metrics to establish impact.
Speaker
Tim Day
Principal
Innovative Strategic Communications
Presentation
Related topics:
Pharmaceutical/Biotech, USA, Medical Affairs & Stakeholder Engagement, Global (non-specific), Life Sciences (not-specific)
Availability: FREE
With the rise of medical affairs as healthcare’s core scientific partner, industry leaders are reimagining their organizations to achieve a world-class standard–and deliver greater value. Learn how to align engagement strategies to healthcare stakeholders’ scientific goals and interests, based on actionable insights.
Speakers
Robert Groebel
Vice President - Global Medical Strategy
Veeva
Brian Harper
Senior Director, Medical Content Strategy
Veeva
Presentation
Related topics:
Pharmaceutical/Biotech, Europe, Market Access & HEOR, Patient-Centricity & Care
Availability: FREE
Speaker
Adrien Gras
Vice President Europe, Market Access
GFK, UK
Presentation
Related topics:
Pharmaceutical/Biotech, Europe, Market Access & HEOR, Biosimilars
Availability: FREE
- How the complex characteristics of biologics (and biosimilars) contribute to perceived value to different stakeholders.
- The salient issues facing Upstarts (marketers of biosimilars) and Defenders (marketers of “original” biologics) in communicating comparative worth to stakeholders.
- How MCDA modelling methods can assist both groups in better defining and communicating value.
Speaker
Mason W. Russell
Vice President, Strategic Consulting (Life Sciences)
Truven, USA
Presentation
Related topics:
Pharmaceutical/Biotech, Europe, Market Access & HEOR
Availability: FREE
- What is driving changes such as conditional market authorisation and adaptive pathways?
- What are the challenges for HTA agencies and their evaluation approaches?
- What are the critical success factors for pharma companies?
Speaker
Anke van Engen
Principal, Consulting Services
QuintilesIMS
Presentation
Related topics:
MedTech, Market Access & HEOR, Asia Pacific
Availability: FREE
- What value does your technology bring to address the needs of the country’s health system?
- How can you develop the market to create a receptive and favorable environment for your technology?
- Case study: Established vs. emerging markets.
Speaker
Anne Smart
Director
Navigant, USA
Presentation
Related topics:
MedTech, Commercial, Global (non-specific), Digital & Technology
Availability: FREE
- Ground breaking technology from Harvard Medical School.
- Used by life science sales teams and healthcare professionals.
- Extend retention of complex processes and facts from weeks to years.
- Mobile and social gaming methods to drive adoption and motivation.
- Maximise return on investment in product training.
Speaker
Louella Morton
VP International Sales & General Manager
Qstream
Presentation
Related topics:
MedTech, Commercial
Availability: FREE
In today’s digital age, marketers can use marketing automation and analytics technology enabling them to be hyper-relevant to the customer via online channels. But what happens when the customer schedules a call or meeting with your sales team? How do you know whether or not your content performs well during this offline phase of the customer journey? Learn how to grow your business by supporting your sales and indirect channels with sales driven marketing.
Speaker
Pieterjan Bouten
Chief Executive Officer
Showpad, Belgium
Presentation
Related topics:
MedTech, Market Access & HEOR, Commercial, Global (non-specific)
Availability: FREE
- Analysis of the real case of a global medical device companythat launched an innovative device to prevent seriouscomplications of a disease and was facing significant market barriers across Europe.
- In spite of the product’s clinical benefits, commercial teams couldnot quantify the value of the product to purchasers and decisionmakers.
- The solution came with the development of a process positioningthe best product evidence to directly address the clinical andeconomic needs of stakeholders.
- Commercial teams were able to quickly demonstrate and quantifyvalue, helping hospitals and clinics to understand the costs and benefits of adopting the medical innovation.
Speaker
Ernesto M. Nogueira
Managing Director
ValueConnected, Netherlands
Presentation
Related topics:
Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific)
Availability: FREE
- Developing and implementing a scientific strategy to effectively disseminate evidence and show value and engaging with diverse stakeholders.
- Understanding how, when, and to whom you communicate evidence.
- Benefits and challenges of consistent communications.
Speaker
Gillian Boucher
Director, Medical Writing and Editorial
Quintiles
Presentation
Related topics:
Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific)
Availability: FREE
- The term “KOL”: Too toxic for everyday use, or still the best tool for the job?
- Results from a survey of pharma and KOLs on the use of terminology alternatives.
- Should pharma work towards using one universal replacement for the term “KOL”?
- How does this change the way we engage with KOLs and stakeholders in medical affairs?
- And what exactly do KOLs think of all this?
Speaker
Sanjay Singhvi
Director
System Analytic, UK
Presentation
Related topics:
Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Global (non-specific)
Availability: FREE
- Defining quality in the context of today’s observational research needs.
- Developing a framework to deliver quality every time you conduct non-interventional studies.
Speaker
Louise Parmenter
Global Head of Operations, Epidemiology & Outcomes Research
Real-World & Late Phase Research
Quintiles
Presentation
Related topics:
Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific), Digital & Technology, Medical Science Liaison
Availability: FREE
Speaker
Gijs Hubben
CEO
BaseCase, Germany
Presentation
Related topics:
Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific)
Availability: FREE
- Evaluating and developing a medical affairs team’s skill sets for more flexibility.
- Developing a life-cycle dependent model for flexible medical affairs resourcing.
- The impact of a flexible resourcing approach on talent acquisition.
- The role of strategic outsourcing for medical affairs.
Speaker
Keith Morris
Vice President, Medical Affairs
Campbell Alliance, USA
Presentation
Related topics:
Pharmaceutical/Biotech, Clinical, Global (non-specific), Oncology
Availability: FREE
- Key challenges in early phase oncology recruitment.
- Therapeutic, supportive and other compounds from trial management perspective.
- Pros and cons of early phase trials for the investigator and for the cancer patient.
- Role and potential of professional CPU (Clinical Pharmacology Unit) within indication.
- Satellite Centre Concept for proper recruitment and controlled quality.
Speaker
Istvan Udvaros
Medical Director, Project Director of Oncology
SGS LSS Clinical Research, Belgium
Presentation
Related topics:
Pharmaceutical/Biotech, Europe, Clinical, Central Eastern Europe, Oncology
Availability: FREE
- Patient pharmacology services: Concept and operational set up.
- ADME concepts, incl. micro-dose and tracer-dose.
- Underlying dossier requirements incl. preclinical safety package.
- General design considerations incl. radiodose and radioburden calculation.
- Devil is in the details: Operational challenges.
- Selection of geographic region and patient population.
- Ethical aspects.
Speaker
Agnes Rethy
Associate Director of Clinical Operations
EDS Patient Pharmacology Services
PRA Health Services
Presentation
Related topics:
Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific), Medical Science Liaison
Availability: FREE
- What is the role of an MSL today in developing strategic relationships with KOLs.
- Learn what a typical ‘day in the life’ of an MSL is like.
- Is the role of an MSL here to stay for the long term?
Speaker
Sital Kotecha
Medical Strategy Director, Europe
Veeva Systems, UK
Presentation
Related topics:
Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific)
Availability: FREE
- The importance and benefits of an effective pre-market communication plan.
- The when, where and how of the various elements who need to be engaged.
- Development and implementation of the plan: Where the magic happens and results are driven!
- The essential elements to any pre-market communication plan.
- The need for achieving balance between the speed, timing and volume of pre-market communications.
Speaker
Tim Day
CEO & Principal
Innovative Strategic Communications, USA
Presentation
Related topics:
Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Global (non-specific)
Availability: FREE
- A review of success rates in recent drug launches.
- Look at where launches haven’t gone well and where RWE could have played a role in mitigating this: The bad.
- Building an Integrated Medical Plan to prepare for success (Begin with the end in mind): The good.
- The resource vs. demand challenge and the consequent benefit of outsourcing: The necessary.
Speaker
Alistair MacDonald
Executive Director, Real World Strategy
INC Research, UK
Presentation
Related topics:
Pharmaceutical/Biotech, Market Access & HEOR, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Global (non-specific)
Availability: FREE
- Regulators and payer considerations of the ‘key value drivers’ in RWE generation.
- Highly successful RWE strategies, study designs and best practices and how they differ across global markets.
- How medical affairs can best utilise RWE to support market access decision making.
Speakers
Leanne Larson
Vice President and Global Head, Observational Research
Parexel, USA
Oliver Leatham
Vice President and Head, Pricing and Market Access
Parexel, UK
Presentation
Related topics:
Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific), Patient-Centricity & Care
Availability: FREE
- Apply a single framework for patient centricity in medical affairs.
- Uncover what patients value and how it changes on their treatment journey.
- Structure and prioritise innovative medical activities in a patientcentric way.
Speaker
Dominic Sloane
Development Director
Adelphi Communications, United Kingdom
Presentation
Related topics:
Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Global (non-specific), Digital & Technology
Availability: FREE
- Challenges facing medical affairs functions today.
- Medical affairs transformation as pipelines shift to specialty care.
- Getting to ‘world class’ through focus on delivering an exceptional stakeholder experience.
Speaker
Sital Kotecha
Medical Strategy Director, Europe
Veeva Systems, UK
Presentation
Related topics:
MedTech, Commercial, Global (non-specific)
Availability: FREE
- Promotion response modelling for ROI on sales calls to derive optimal size.
- Territory alignment based on Potential Index and Workload Index.
- Incentive design for salesforce based on fairness, motivation and financial risk.
Speaker
Sumit Mehta
Managing Director
Cetas Healthcare Insights
Presentation
Related topics:
MedTech, Commercial, Global (non-specific)
Availability: FREE
- Identifying commercial learning challenges.
- Shifting middle performers.
- Implementing solutions to support continuous commercial learning at scale.
- The path to continued commercial effectiveness.
Speakers
Jay Bratcher
Training Manager, New Cardio, Europe
Boston Scientific, UK
Michael Quann
Director Strategic Account
Qstream, Ireland
Presentation
Related topics:
MedTech, Market Access & HEOR, Commercial, Global (non-specific)
Availability: FREE
- Overview of the main reimbursement systems in Europe.
- Price: The main barrier for medical technology.
- When is it (really) necessary to apply for reimbursement?
- Demonstrating value to access healthcare payment pathways.
- Moving ahead: The new EU perspective on medical innovations.
Speaker
Ernesto Nogueira
Managing Director
ValueConnected
Presentation
Related topics:
MedTech, Market Access & HEOR, Commercial, Global (non-specific)
Availability: FREE
Prioritising and targeting the best business opportunities is crucial for medical device
companies to create an optimal offering strategy while controlling and minimising
discounting. Therefore it is critical for global pricing, commercial and marketing
leaders to standardise their price configuration, quotes and tender processes with
best practices. This approach will lead to new business and optimal deal structures,
resulting in higher revenues and margins.
Speaker
James Robinson
Director Industry Solutions
ModelN, Switzerland
Presentation
Related topics:
Pharmaceutical/Biotech, Clinical, Middle East
Availability: FREE
- Why is recruitment important?
- Issues seen in studies (generally not just MENA).
- What are the possible reasons for this?
- Are there differences between MENA and ROW in patient recruitment numbers and retention rates?
- How could we actively prevent these issues?
- Case studies (both good and bad) & lessons learned.
Speaker
Myriam El-Khazen
General Manager
INC Research, Greece
Presentation
Related topics:
Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Asia Pacific
Availability: FREE
Speaker
Karen Wai
Vice President, Regional Managing Director Real-World & Late Phase Research, Asia Pacific
Quintiles, Singapore
Presentation
Related topics:
Pharmaceutical/Biotech, Medical Affairs & Stakeholder Engagement, Real-World Evidence & Late-Phase Research, Asia Pacific
Availability: FREE
- Current state of RWE in Asia markets.
- Key trends and how it is evolving.
- What this means for healthcare companies.
Speaker
Sheryl Jacobson
Asia Head of Life Science and Healthcare Consulting
Deloitte
Presentation
Related topics:
Pharmaceutical/Biotech, IT & Big Data, Global (non-specific), Digital & Technology
Availability: FREE
- An ever-increasing number of individuals routinely contribute and consume solicited and unsolicited information about a variety of health-related issues using a wide range of internet and social media channels.
- Personal web-based reports on health status, symptoms, treatments and associated interventions may provide a rich source of data to support discovery, clinical development and post marketing analytics.
- A key challenge in the applicability and utility of these data is related to the veracity, accuracy and reliability of information collected from web-based media sources.
Speaker
Mark Wolff
Advisory Industry Consultant, Chief Health Analytics Strategist
Health & Life Sciences Global Practice, SAS Institute, USA
Presentation
Related topics:
Pharmaceutical/Biotech, IT & Big Data, Global (non-specific), Patient-Centricity & Care, Digital & Technology
Availability: FREE
Speaker
Alexander Frenzel
Senior Manager, Business Development T&A, QuintilesIMS, Germany
Presentation
Related topics:
Pharmaceutical/Biotech, Clinical, IT & Big Data, Discovery & R&D Innovation, Global (non-specific)
Availability: FREE
Speaker
Jonathan Sheldon
Global Vice President, Healthcare | Health Sciences
Global Business Unit, Oracle Health Sciences, UK
Presentation
Related topics:
Pharmaceutical/Biotech, Real-World Evidence & Late-Phase Research, Clinical, IT & Big Data, Global (non-specific)
Availability: FREE
Speaker
John Rigg
Head of Predictive Analytics Real-World Insights, QuintilesIMS, UK
Presentation
Related topics:
Pharmaceutical/Biotech, IT & Big Data, Discovery & R&D Innovation, Global (non-specific)
Availability: FREE
- Convergence of data, technology and advances in the field ofneural networks.
- Increased opportunities for the use of real-world evidence data sets from the genome revolution, clinical trials, medical imaging and electronic health records.
- Accelerate the use of Artificial Intelligence (AI) within Pharma R&D to develop actionable insights.
Speaker
Andrea de Souza
Global Business Development Lead, NVIDIA, USA
Presentation
Related topics:
Pharmaceutical/Biotech, Clinical, IT & Big Data, Discovery & R&D Innovation, Global (non-specific)
Availability: FREE
- Identify new patient target groups for innovative drug development by applying predictive analytics to real world and trial data.
- Enhance R&D productivity by mapping the real world using predictive analytics.
- Facilitate the implementation of Adaptive Pathways through predictive analytics.
Speakers
Kerstin Bode-Greuel
Dir. Business Development & Marketing RWE
QuintilesIMS, Germany
Rolf Günther
Chief Information Officer
Qlaym Healthcare, Germany